International
The Morning Science

What science found today

‹
 

News

FDA OKs First Drug for Primary Membranous Nephropathy

MedPage Today ·

FDA OKs First Drug for Primary Membranous Nephropathy

The Brief

  • The FDA expanded the label for the B-cell depleter obinutuzumab (Gazyva) to include treatment of primary membranous nephropathy.
  • MedPage Today describes this as the first drug approved for primary membranous nephropathy.
  • The FDA announced the new indication on a Friday; the source snippet does not give the exact date or the full conditions of use.

Why it matters

It adds an approved drug option for a kidney disease, which matters to science readers following how laboratory and clinical research becomes treatment.

Who’s affected

  • physicians treating kidney disease
  • patients with primary membranous nephropathy

(MedPage Today) -- The FDA has once again expanded the label for the B-cell depleter obinutuzumab (Gazyva), this time to include treatment of primary membranous nephropathy. The new indication, announced by the agency on Friday, stipulates use...

How do you feel about this?

0 Comments

    FDA OKs First Drug for Primary Membranous Nephropathy – The Morning Science